- Home
- PALI vs THAR Comparison
PALI vs THAR Comparison
Compare PALI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- THAR
- Stock Information
- Founded
- PALI 1996
- THAR 2017
- Country
- PALI United States
- THAR United States
- Employees
- PALI N/A
- THAR N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- THAR Health Care
- Exchange
- PALI Nasdaq
- THAR Nasdaq
- Market Cap
- PALI 3.5M
- THAR 2.8M
- IPO Year
- PALI N/A
- THAR 2022
- Fundamental
- Price
- PALI $1.75
- THAR $2.10
- Analyst Decision
- PALI Strong Buy
- THAR
- Analyst Count
- PALI 2
- THAR 0
- Target Price
- PALI $23.00
- THAR N/A
- AVG Volume (30 Days)
- PALI 3.7M
- THAR 222.9K
- Earning Date
- PALI 11-12-2024
- THAR 11-07-2024
- Dividend Yield
- PALI N/A
- THAR N/A
- EPS Growth
- PALI N/A
- THAR N/A
- EPS
- PALI N/A
- THAR N/A
- Revenue
- PALI N/A
- THAR N/A
- Revenue This Year
- PALI N/A
- THAR N/A
- Revenue Next Year
- PALI N/A
- THAR N/A
- P/E Ratio
- PALI N/A
- THAR N/A
- Revenue Growth
- PALI N/A
- THAR N/A
- 52 Week Low
- PALI $1.38
- THAR $1.84
- 52 Week High
- PALI $22.35
- THAR $8.42
- Technical
- Relative Strength Index (RSI)
- PALI 40.97
- THAR 43.79
- Support Level
- PALI $1.59
- THAR $2.09
- Resistance Level
- PALI $2.20
- THAR $2.27
- Average True Range (ATR)
- PALI 0.39
- THAR 0.18
- MACD
- PALI 0.02
- THAR -0.01
- Stochastic Oscillator
- PALI 19.27
- THAR 17.02
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.